Valneva (VALN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.40
- Estimate
- -$0.08
- Surprise
- -395.4%
- Score today
- 4.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Valneva (VALN) reported a wider loss than forecast — diluted EPS of -$0.40 against the -$0.08 estimate (a 395.4% shortfall).
Coverage in the report window
- European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application — benzinga, 2026-08-14
- Dow Falls Over 100 Points; US Consumer Sentiment Declines In August — benzinga, 2026-08-14
- Heartflow, Eton Pharmaceuticals, Nu Holdings And Other Big Stocks Moving Higher On Friday — benzinga, 2026-08-14
Where TrendMatrix's rating stands now
TrendMatrix currently rates VALN Sell at 4.6/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -395.4% surprise compares with a -200.1% four-quarter average. Next scheduled report: 2027-03-17.
What argues against it
- Quality below floor (1.9 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin 0.6%), Material insider selling (8 sells, 0.10% of cap)
- Momentum score 3.8/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.96
- Price target
- $10.41
- Stop
- $6.47
- Upside to target
- +49.6%
- Reward-to-risk
- 3.3:1
Risk check: RSI 85 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
VALN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $660.0M
- P/E (fwd)
- 5.8
- 52-week range
- $4.75–$12.23
- Off 52-week high
- 43.1%
- RSI (14)
- 85
- Volume vs avg
- 0.12×
- Score today
- 4.6/10